Martin is an HTA expert and has been an advisor with NDA since 2011. He specialises in the rapidly developing methodology and practice of economic evaluation of health technologies. Martin applies his expertise to ensure that pharmaceutical companies and device manufacturers are aware of the latest requirements for NICE approval, and can identify the strategies they need to adopt in order to maximise reimbursement opportunities in the UK and in other jurisdictions where cost-effectiveness is a key criterion.
Key Areas Of Expertise
- More than forty years involvement in the development of economic evaluation
- Direct involvement in applying economic evaluation to a diverse range of health technologies and methodological development to support such evaluation and to assist in its use in policy.
- Advisory roles to the UK Department of Health and Social Care, and its agencies.
- Explaining and teaching health economics at all levels from short courses to PhD supervisions.
Before joining the NDA Advisory Board
Martin was Professor of Health Economics at Brunel University London. There he founded the Health Economics Research Group and built it up into one of the leading academic research groups in the field, conducting reasearch mainly funded by the Department of Health, Medical Research Council and other public sources.
He has been a member of: the Technology Appraisal Committee of the National Institute for Health and Care Excellence (and various of its working groups); the UK National Screening Committee, and several UK and international expert panels. He is currently one of the panel of experts used by NICE’s Scientific Advice Programme.
In 2010 he was awarded the Avedis Donabedian Lifetime Achievement Award by the International Society for Pharmaco-economics and Outcomes Research
Grant J, Buxton MJ. Economic returns to medical research funding. BMJ Open 2018; 8 (9) e022131. doi:10.1136/bmjopen-2018-022131
Glover M, Montague E, Pollitt A, Guthrie S, Hanney S, Buxton M, Grant J (2018) Estimating the returns to United Kingdom publicly funded musculoskeletal disease research in terms of net value of improved health outcomes. Health Research Policy and Systems 2018 16:1 https://doi.org/10.1186/s12961-017-0276-7
Buxton M, Longworth L, Raftery J, Sculpher M, Towse A (2014). Reforming the cancer drug fund. BMJ (Online), 349. doi:10.1136/bmj.g7276
Glover M, Buxton MJ, Guthrie S, Hanney S, Pollitt A, Grant J (2014) Estimating the returns to UK publicly funded cancer-related research in terms of the net value of improved health outcomes.BMC Medicine 2014, 12:99 doi:10.1186/1741-7015-12-99
Glover MJ, Kim LG, Sweeting MJ, Thompson SG, Buxton MJ (2014) Cost-effectiveness of the National Health Service abdominal aortic aneurysm screening programme in England. British Journal of Surgery 101(8), 976-982. doi:10.1002/bjs.9528
Professor Martin Buxton